0000950170-22-002556 | 10-K | XBRL Viewer

Estimated Useful

Description

Life (in years)

Customer relationships

Tradenames

Total acquired intangibles

Print Document View Excel Document

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 116,762	$ 160,802
Short-term investments	36,279	48,599
Accounts receivable, net of allowance for doubtful accounts of $3,418 and $3,654	45,323	38,835
Inventories	53,138	31,863
Prepaid expenses	7,939	3,860
Other current assets	28,990	4,934
Total current assets	288,431	288,893
Noncurrent Assets:
Property, plant and equipment, net	88,164	51,860
Operating right-of-use assets, net	9,056	4,461
Finance right-of-use assets, net	2,493	1,312
Intangible assets, net	14,343	17,904
Goodwill	40,279	40,351
Long-term investments	17,009	47,718
Other noncurrent assets	1,215	1,973
Total noncurrent assets	172,559	165,579
TOTAL ASSETS	460,990	454,472
Current Liabilities:
Accounts payable	28,024	17,407
Deferred revenue	2,936	4,811
Accrued expenses and other current liabilities	33,778	22,227
Finance lease liability	939	517
Operating lease liability	2,181	1,125
Acquisition-related contingent consideration obligation	206	402
Total current liabilities	68,064	46,489
Noncurrent Liabilities:
Finance lease liability	1,952	895
Operating lease liability	7,202	3,591
Acquisition-related contingent consideration obligation	354	2,049
Other noncurrent liabilities	651	1,682
Deferred income taxes	2,234	1,195
Total noncurrent liabilities	12,393	9,412
TOTAL LIABILITIES	80,457	55,901
COMMITMENTS AND CONTINGENCIES (Note 15)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 72,069 and 71,738 shares issued and outstanding	0	0
Additional paid-in capital	511,063	505,123
Accumulated other comprehensive loss	(10,077)	(9,097)
Accumulated deficit	(120,453)	(97,455)
Total stockholders' equity	380,533	398,571
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 460,990	$ 454,472

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,418	$ 3,654
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	72,069,000	71,738,000
Common stock, shares outstanding	72,069,000	71,738,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
NET REVENUES:
Total revenue	$ 233,674	$ 171,721	$ 154,605
COST OF PRODUCTS AND SERVICES SOLD	116,074	69,853	60,022
Gross profit	117,600	101,868	94,583
OPERATING EXPENSES:
Research and development	34,170	31,032	19,629
Sales and marketing	44,751	34,459	31,869
General and administrative	50,328	42,653	35,287
Change in the estimated fair value of acquisition-related contingent consideration	(1,485)	(1,099)	(664)
Gain on sale of business			(10,149)
Total operating expenses	127,764	107,045	75,972
Operating income (loss)	(10,164)	(5,177)	18,611
OTHER INCOME	872	1,653	2,720
Income (loss) before income taxes	(9,292)	(3,524)	21,331
INCOME TAX EXPENSE	13,706	11,398	4,675
NET INCOME (LOSS)	$ (22,998)	$ (14,922)	$ 16,656
INCOME (LOSS) PER SHARE:
BASIC	$ (0.32)	$ (0.22)	$ 0.27
DILUTED	$ (0.32)	$ (0.22)	$ 0.27
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,981	67,505	61,675
DILUTED	71,981	67,505	62,170
Products and Services [Member]
NET REVENUES:
Total revenue	$ 226,897	$ 166,381	$ 148,073
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 6,777	$ 5,340	$ 6,532

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ (22,998)	$ (14,922)	$ 16,656
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	(894)	3,273	5,767
Unrealized gain (loss) on marketable securities	(86)	(234)	803
COMPREHENSIVE INCOME (LOSS)	$ (23,978)	$ (11,883)	$ 23,226

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2018	$ 283,378		$ 401,273	$ (18,706)	$ (99,189)
Beginning Balance, Shares at Dec. 31, 2018		61,276
Common stock issued upon exercise of options	196		196
Common stock issued upon exercise of options, Shares		27
Vesting of restricted stock, Shares		717
Purchase and retirement of common shares	(3,712)		(3,712)
Purchase and retirement of common shares, Shares		(289)
Stock-based compensation	4,057		4,057
NET INCOME (LOSS)	16,656				16,656
Currency translation adjustments	5,767			5,767
Unrealized gain (loss) on marketable securities	803			803
Ending Balance at Dec. 31, 2019	307,145		401,814	(12,136)	(82,533)
Ending Balance, Shares at Dec. 31, 2019		61,731
Common stock issued upon exercise of options	3,222		3,222
Common stock issued upon exercise of options, Shares		402
Vesting of restricted stock and performance stock units, Shares		653
Purchase and retirement of common shares	(2,088)		(2,088)
Purchase and retirement of common shares, Shares		(248)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200	95,036		95,036
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares		9,200
Stock-based compensation	7,139		7,139
NET INCOME (LOSS)	(14,922)				(14,922)
Currency translation adjustments	3,273			3,273
Unrealized gain (loss) on marketable securities	(234)			(234)
Ending Balance at Dec. 31, 2020	398,571		505,123	(9,097)	(97,455)
Ending Balance, Shares at Dec. 31, 2020		71,738
Common stock issued upon exercise of options	$ 246		246
Common stock issued upon exercise of options, Shares	33	33
Vesting of restricted stock and performance stock units, Shares		451
Purchase and retirement of common shares	$ (2,113)		(2,113)
Purchase and retirement of common shares, Shares		(153)
Stock-based compensation	7,807		7,807
NET INCOME (LOSS)	(22,998)				(22,998)
Currency translation adjustments	(894)			(894)
Unrealized gain (loss) on marketable securities	(86)			(86)
Ending Balance at Dec. 31, 2021	$ 380,533		$ 511,063	$ (10,077)	$ (120,453)
Ending Balance, Shares at Dec. 31, 2021		72,069

Consolidated Statements of Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common stock in connection with public offering, net of commissions and expenses	$ 6,200

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
OPERATING ACTIVITIES:
Net income (loss)	$ (22,998)	$ (14,922)	$ 16,656
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	7,807	7,139	4,057
Depreciation and amortization	11,658	9,387	7,339
Other non-cash amortization	837	327	391
Provision for doubtful accounts	(253)	941	2,248
Inventory reserve	6,731	736	(280)
Unrealized foreign currency (gain) loss	(210)	269	385
Interest expense on finance leases	82	72	36
Deferred income taxes	1,026	(392)	(1,457)
Loss on sale of fixed assets		114	147
Gain on sale of product line		(225)
Gain on sale of business			(10,149)
Change in fair value during the period	(1,485)	(1,099)	(664)
Payment of acquisition related contingent consideration	(142)	(496)
Changes in assets and liabilities
Accounts receivable	(6,451)	(2,324)	(2,210)
Inventories	(27,941)	(9,343)	(1,044)
Prepaid expenses and other assets	(8,674)	(104)	200
Accounts payable	3,234	7,379	(1,537)
Deferred revenue	(1,891)	1,051	(297)
Accrued expenses and other liabilities	3,288	7,297	(4,017)
Net cash (used in) provided by operating activities	(35,382)	5,807	9,804
INVESTING ACTIVITIES:
Purchases of investments	(25,822)	(90,137)	(92,173)
Proceeds from maturities and redemptions of investments	67,925	107,718	93,491
Purchases of property and equipment	(36,622)	(26,674)	(9,314)
Purchase of property and equipment under government contracts	(11,495)
Proceeds from funding under government contract	531
Purchase of patent and product rights		(2,250)
Acquisition of businesses, net of cash acquired		(3,037)	(23,801)
Proceeds from sale of business			12,000
Other investing activities	(18)	351
Net cash used in investing activities	(5,501)	(14,029)	(19,797)
FINANCING ACTIVITIES:
Repayments of loans			(724)
Cash payments for lease liability	(686)	(687)	(442)
Issuance of common stock in connection with public offering, net		95,036
Proceeds from exercise of stock options	246	3,222	196
Payment of acquisition related contingent consideration	(264)	(3,004)
Repurchase of common stock	(2,113)	(2,088)	(3,712)
Net cash (used in) provided by financing activities	(2,817)	92,479	(4,682)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(340)	830	1,952
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(44,040)	85,087	(12,723)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	160,802	75,715	88,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 116,762	$ 160,802	$ 75,715

The Company

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

1. THE COMPANY:

The overall goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment, and our “Molecular Solutions” segment.

Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Diagnostics business includes tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests for drugs of abuse that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our COVID-19 and HIV products are also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our Diagnostics business also includes the operations of UrSure, Inc. (“UrSure”), which was acquired and merged into OraSure in 2020. This part of the Diagnostics business develops and commercializes products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medications in a patient’s urine or blood, as well as point-of-care products currently in development. In 2020, we began developing a rapid antigen self-test for COVID-19 and a COVID-19 antibody enzyme-linked immunosorbent assay (“ELISA”) for use in laboratory settings. In June 2021, we received three Emergency Use Authorizations ("EUA") from the U.S. Food and Drug Administration ("FDA") for our InteliSwab® COVID-19 Rapid Tests for non-prescription OTC, professional point-of-care (Clinical Laboratory Improvements Amendment of 1988, or "CLIA," waived) and prescription use. We began recording revenues on the sales of our InteliSwab® COVID-19 Rapid Tests during the third quarter of 2021. Following discussions with the FDA and their de-prioritization of antibody testing in the U.S., we decided to no longer pursue an EUA for the ELISA antibody test. We have, however, continued to offer the product for research use to labs and other parties interested in COVID antibody surveillance and research applications.

Our Molecular Solutions business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). In our Molecular Solutions business, we manufacture and sell kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. Our products are used for academic research and commercial applications, including ancestry, disease risk management, lifestyle and animal testing. Three of our collection devices are used in connection with COVID-19 molecular testing. We also sell research-use-only collection products into the microbiome market. We offer our customers a suite of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, which includes the operations of CoreBiome, Inc. (“CoreBiome”), a subsidiary we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for use in research, screening and diagnostics in the liquid biopsy and sexually transmitted infection markets. Our Molecular Solutions business serves customers in many countries worldwide, including many leading research universities and hospitals.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as

calculations related to accruals, taxes, contingent consideration and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Employee Retention Credit

In December 2021, we applied for the Employee Retention Credit for payroll taxes paid in the first and second quarters of 2021 as provided by the Coronavirus Aid, Relief and Economic Security Act. The amount due from the Internal Revenue Service of $5,728 is recorded in other current assets in our consolidated balance sheet as of December 31, 2021. The credit is reported in our consolidated statement of operations, for the year ended December 31, 2021, within cost of products and services sold, research and development, sales and marketing and general and administrative costs in the amounts of $2,536, $1,134, $924, and $1,134, respectively

Supplemental Cash Flow Information

In 2021, 2020 and 2019, we paid income taxes of $13,727, $9,263 and $10,611, respectively.

In 2021, 2020 and 2019, we recorded through the consolidated statements of operations an increase (decrease) in our allowance for doubtful accounts of $(253), $941 and $2,248 respectively. We had write-offs of $115, $501 and $110 in 2021, 2020, and 2019, respectively.

As of December 31, 2021, 2020 and 2019, we had accruals for purchases of property and equipment of $8,166 $802, and $660, respectively.

Investments

We consider all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. During 2021, we recognized a provision for expected credit losses for our available-for-sale securities of $98.

The following is a summary of our available-for-sale securities as of December 31, 2021 and 2020:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2021
Guaranteed investment certificates	$	33,249	$	—	$	—		$	33,249
Corporate bonds		20,473		—		(434	)		20,039
Total available-for-sale securities	$	53,722	$	—	$	(434	)	$	53,288
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At December 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	36,386	$	—	$	(107	)	$	36,279
Greater than one year	$	17,336	$	—	$	(327	)	$	17,009

Fair Value of Financial Instruments

As of December 31, 2021 and 2020, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2021 and 2020. Our guaranteed investment certificates are measured as Level 1 instruments as of December 31, 2021 and 2020.

Included in cash and cash equivalents at December 31, 2021 and 2020, was $1,160 and $71,489 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2021 and 2020 was $1,763 and $2,565, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

As further discussed in Note 3, Business Combinations, we have identified our contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations.

The following table represents the change in contingent consideration:


Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain

circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are typically depreciated over twenty years, while computer equipment and software, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our annual impairment assessment as of July 31, 2021 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our reporting units is greater than their carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting units. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs.

Revenue

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.

We generally do not grant product return rights to our customers, except for warranty returns and return rights on sales of our OraQuick® In-Home HIV test to the retail trade, and InteliSwab® products to certain customers.

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. We recognize revenues when we satisfy our performance obligations for services rendered.

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, which largely applies to our service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.

Other revenues. Other revenues consist primarily of royalty income, funding of research and development efforts and cost reimbursements under a charitable support agreement. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are being performed in accordance with the respective agreements.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2021 and 2020 included customer prepayments of $1,843 and $3,216, respectively. Deferred revenue as of December 31, 2021 and 2020 also included $1,093 and $1,595, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined based on expected revenues and revenue is recognized at that rate when the product is delivered to the customer.

Financing and Payment. Our payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, we defer the cost of the commission and expense it over the life of the related sales contract.

Revenues by product. The following table represents total net revenues by product line:


	Years ended December 31,
	2021		2020		2019
Infectious disease testing	$	54,645	$	54,227	$	58,016
Risk assessment testing		9,678		9,194		12,189
Cryosurgical systems		-		-		7,054
Genomics (1)		63,350		36,878		56,200
Microbiome (1)		7,944		5,474		7,172
COVID-19 (1)		76,874		50,927		-
Laboratory services		11,840		8,746		6,767
Other product and service revenues		2,566		935		675
Net product and services revenues		226,897		166,381		148,073
Royalty income		4,420		3,432		5,116
Other non-product revenues		2,357		1,908		1,416
Other revenues		6,777		5,340		6,532
Net revenues	$	233,674	$	171,721	$	154,605

(1) 2020 Genomics, Microbiome, and COVID-19 revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the year ended December 31, 2020 by $(263), $(682), and $945, respectively.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	Years ended December 31,
	2021		2020		2019
United States	$	188,383	$	130,835	$	107,279
Europe		13,799		12,068		11,752
Other regions		31,492		28,818		35,574
	$	233,674	$	171,721	$	154,605

Customer and Vendor Concentrations. We had no customers that accounted for more than 10% of our accounts receivable as of December 31, 2021. We had one customer that accounted for 11% of our accounts receivable as of December 31, 2020. The same customer accounted for approximately 15% of our net consolidated revenues for the year ended December 31, 2019. We had no customers that accounted for more than 10% of our consolidated net revenues for the years ended December 31, 2021 and 2020.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

DNAG has three long-term contract manufacturing relationships to supply virtually all of its products, including the Oragene® product line. Many of the raw materials and components used in these products are also purchased from third parties, some of which are purchased from a single source supplier. We are actively seeking to qualify other suppliers that can manufacture and supply the raw materials and components for the DNAG products.

Business Combinations and Contingent Consideration

Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires us to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although we believe the assumptions and estimates we have made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.

We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of our consideration for the recent acquisitions, we are contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, we are required to update our underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations. Our estimates of fair value are based on assumptions we believe to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on our results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates.

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:

•

future expected cash flows from sales and acquired developed technologies;

•

the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;

•

the probability of meeting the future events; and

•

discount rates used to determine the present value of estimated future cash flows.

These estimates are inherently uncertain and unpredictable, and if different estimates were used the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that we have made. In addition, unanticipated

events and circumstances may occur, which may affect the accuracy or validity of such estimates, and if such events occur we may be required to record a charge against the value ascribed to an acquired asset or an increase in the amounts recorded for assumed liabilities.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2021, 2020, and 2019, we incurred $5,103, $1,126, and $468, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange losses resulting from foreign currency transactions that are included in other income in our consolidated statements of operations were $(667), $(337), and $(1,339) for the years ended December 31, 2021, 2020, and 2019, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares

of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

The computations of basic and diluted earnings (loss) per share are as follows:


	Years ended December 31,
	2021			2020			2019

Net income (loss)	$	(22,998	)	$	(14,922	)	$	16,656
Weighted-average shares of common stock outstanding:
Basic		71,981			67,505			61,675
Dilutive effect of stock options, restricted stock, and performance stock units		—			—			495
Diluted		71,981			67,505			62,170
Earnings (loss) per share:
Basic	$	(0.32	)	$	(0.22	)	$	0.27
Diluted	$	(0.32	)	$	(0.22	)	$	0.27

For the years ended December 31, 2021 and 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 769 and 984 shares, respectively, were excluded from the computation of diluted loss per share.

For the year ended December 31, 2019 outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 768 were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2021 consists of $9,643 of currency translation adjustments and $434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2020 consists of $8,749 of currency translation adjustments and $348 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements

In November 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, The purpose of this update is to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in their financial statements . Required disclosures include i) the nature of the transactions and related accounting policy used, ii) the financial statement line items affected and amounts thereof and iii) significant terms and conditions of the transactions. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, with early application permitted. We have adopted this guidance within this 2021 Form 10-K. See Note 5 for required disclosures.

Business Combinations

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Business Combinations

3. BUSINESS COMBINATIONS

UrSure

On July 22, 2020, the Company acquired all of the outstanding stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $3,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement.

During the year ended December 31, 2020, we incurred a total of $393 of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020.

Pursuant to our acquisition agreement, we may pay up to an additional $28,000 of contingent consideration over the three years following the acquisition date based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the achievement of certain clinical milestones associated with the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $3,440. The fair value was determined using a probability-weighted model based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.

The following table represents the change in contingent consideration:


Estimated fair value of contingent consideration as of acquisition date	$	3,440
Change in fair value during the period		(989	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

The change in fair value during the years ended December 31, 2021 and 2020 is a result of delays in achieving certain product development milestones and a decrease in associated revenue forecasts as result of these delays.

Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure are included in our Diagnostics segment.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,600
Goodwill		3,586
Total assets acquired		7,501
Liabilities Assumed
Current liabilities		335
Deferred tax liability		689
Total liabilities assumed		1,024
Net Assets Acquired		6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, which is subject to amortization on a straight-line basis and is being amortized over a ten year estimated useful life.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of UrSure. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisition was a result of gaining a complementary product offering that will enable us to leverage those products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Diagnostics segment.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed, related to the acquisition. Additional information that existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Diversigen

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen pursuant to the terms of a merger agreement. The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above.

During the year ended December 31, 2019, we incurred a total of $1,198 of acquisition related costs, including investment banking fees and accounting, legal and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2019.

Pursuant to the merger agreement, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements which did not occur.

Revenues from Diversigen primarily consist of microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our Molecular Solutions segment.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,458
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,458

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of Diversigen. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Molecular Solutions segment.

CoreBiome and Novosanis

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. CoreBiome has subsequently been merged into Diversigen in December 2020. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the year ended December 31, 2019, we incurred a total of $639 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operation.

Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $3,612 as of December 31, 2019. This change was a result of changes in our estimated revenue forecasts and an amendment to one of the agreements, entered into in October 2019, in which management agreed to settle the contingent consideration associated with one of the acquisition’s 2019 results for $3,500. The fair value of the contingent consideration obligation changed from $3,612 as of December 31, 2019 to $0 as of December 31, 2020. This change is a result of a $3,500 payment made in the first quarter of 2020, changes in our estimated revenue forecasts and an amendment to one of the agreements.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our Molecular Solutions segment.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:


	Estimated Useful
Description	Life (in years)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Molecular Solutions segment.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the UrSure, Diversigen, CoreBiome and Novosanis acquisitions as if they had been consummated as of January 1, 2019. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the

acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2019.


	Year Ended December 31,
	2020			2019

Revenue	$	172,563		$	159,632
Net income (loss)		(14,937	)		16,261
Net income (loss) per share, basic		(0.22	)		0.26
Net income (loss) per share, diluted		(0.22	)		0.26

Sale of Cryosurgical Business

12 Months Ended

Dec. 31, 2021

Discontinued Operations and Disposal Groups [Abstract]

Sale of Cryosurgical Business

4. SALE OF CRYOSURGICAL BUSINESS

On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical systems line of business to

a third party for $12,000. This business consisted of medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The products were sold in both the professional and OTC markets in North America, Europe, Central and South America and Australia. We also entered into a transition services agreement with CryoConcepts in which both parties agreed to provide certain transition services beginning after the closing. The Company recorded a gain on sale of business of $10,149 reflected in our statement of operations for the year ended December 31, 2019. The gain includes the $12,000 of proceeds net of the fair value of the assets sold, which consisted entirely of inventory and fully-depreciated fixed assets, the legal fees associated with the transaction, and a value attributed to the transition services.

Government Capital Contracts

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Government Capital Contracts

5. GOVERNMENT CAPITAL CONTRACTS:

In September 2021, we entered into an agreement for $109,000 in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for our InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. Funding will be paid to the Company based on achievement of milestones through March 2024 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15% of the total will not be funded until the completion of the final validation testing, which is scheduled to occur in late 2023 and early 2024. We began making payments to vendors for the capital project during the fourth quarter of 2021. We began receiving funds from the DOD in January 2022 and had received $15,428 as of the date of this report.

Additionally, during 2021, we received $531 in funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for the purchase of machinery and equipment as part of an expansion of manufacturing operations in Pennsylvania. All related purchases were completed in 2021.

Activity for these capital contracts is accounted for pursuant to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding earned in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Amounts earned in excess of our expected cost of the project for project management are recognized straight-line in other income over the term of the government contract. We recognized $561 of such income, which is reported as other income in our consolidated statement of operations for the year ended December 31, 2021.

The balances corresponding to government contracts included in our consolidated balance sheet as of December 31, 2021, are as follows:


	December 31, 2021
Other current assets:
Billed receivables	$	9,913
Unbilled receivables		9,716
Total other current assets		19,629
Property, plant and equipment, net:
Cost of assets		11,495
Reduction for funding earned, not yet received		(10,964	)
Reduction for funding received		(531	)
Total property, plant and equipment, net		-
Accrued expenses and other current liabilities		(8,103	)

Inventories

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Inventories

INVENTORIES:


	December 31,
	2021		2020
Raw materials	$	33,168	$	15,425
Work in process		2,252		2,572
Finished goods		17,718		13,866
	$	53,138	$	31,863

During 2021, 2020, and 2019, we recorded adjustments to inventory which had a cost of $13,400, $2,564, and $1,318, respectively. The adjustments in 2021 included a write-off of $3,008 of COVID-19 antibody inventory, which we do not believe we can sell as a result of the decision to no longer pursue an EUA for the ELISA antibody test. Additionally, a significant portion of our 2021 adjustments were related to production and tech-transfer issues associated with our COVID-19 rapid test.

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

7. PROPERTY, PLANT AND EQUIPMENT:


	December 31,
	2021			2020
Land	$	1,118		$	1,118
Buildings and improvements		35,420			26,480
Machinery and equipment		57,919			36,878
Computer equipment and software		14,700			13,024
Furniture and fixtures		4,228			3,545
Construction in progress		35,936			24,419
		149,321			105,464
Less accumulated depreciation		(61,157	)		(53,604	)
	$	88,164		$	51,860

Depreciation expense was $7,498, $5,514, and $4,421 for 2021, 2020, and 2019, respectively.

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

8. GOODWILL AND OTHER INTANGIBLE ASSETS:

The following table represents total goodwill by operating segment:


	December 31,
	2021		2020
Diagnostics	$	3,604	$	3,586
Molecular Solutions		36,675		36,765
	$	40,279	$	40,351

The changes in goodwill are as follows:


	December 31,
	2021			2020
Balance as of January 1		40,351			36,201
Goodwill acquired during the year		—			3,586
Purchase price adjustment		18			(126	)
Change related to foreign currency translation		(90	)		690
Balance as of December 31	$	40,279		$	40,351

Intangible assets consist of the following:


			December 31, 2021
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	15,016	$	(11,205	)	$	3,811
Patents and product rights		5		7,785		(6,241	)		1,544
Developed technology	7-10			16,293		(9,725	)		6,568
Tradename	5-15			5,661		(3,241	)		2,420
			$	44,755	$	(30,412	)	$	14,343


			December 31, 2020
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	14,997	$	(9,685	)	$	5,312
Patents and product rights		5		7,766		(5,792	)		1,974
Developed technology	7-10			16,603		(8,880	)		7,723
Tradename	5-15			5,645		(2,750	)		2,895
			$	45,011	$	(27,107	)	$	17,904

Amortization expense for 2021, 2020, and 2019 was $3,260, $3,246, and $2,522, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2022		2,305
2023		2,305
2024		2,265
2025		2,012
2026		1,630
Beyond		3,826
	$	14,343

Accrued Expenses

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Accrued Expenses

9. ACCRUED EXPENSES:


	December 31,
	2021		2020
Payroll and related benefits	$	15,570	$	14,769
Commitment to purchase under government contract		8,103		—
Professional fees		3,335		978
Sales tax payable		2,227		2,400
Other		4,543		4,080
	$	33,778	$	22,227

Leases

12 Months Ended

Dec. 31, 2021

Lessee Disclosure [Abstract]

Leases

. LEASES:

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2021, we are the lessee in all agreements. Our leases have remaining

lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components. During 2021, we entered into various purchase agreements for our molecular solutions business which include a finance lease component for the use of specialized molds made and used by the vendor for purposes of manufacturing the goods to be purchased. We recorded an aggregate ROU asset and offsetting lease liability of $2,074 upon commencement of these contracts. The consideration to be paid under the agreements is variable based on the amounts purchased with a fixed amount charged if specified purchase minimums are not met. Only the fixed amount has been included in the measurement of the finance right-of-use asset and lease liability and the variable costs are recognized as purchases are made within cost of products and services sold in our consolidated statements of operations. The consideration for the contract has been allocated between the lease and non-lease components based on their relative estimated stand-alone selling prices.

The components of lease expense are as follows:


	Years ended December 31,
	2021		2020		2019
Operating lease cost	$	2,226	$	1,291	$	964
Variable lease cost		201		—		—
Finance lease cost:
Amortization of right-of use assets		900		627		410
Interest on lease liabilities		82		72		36
Total finance lease cost		982		699		446
Total lease cost	$	3,409	$	1,990	$	1,410

Supplemental cash flow information related to leases is as follows:


	Years ended December 31,
	2021		2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,733	$	1,280	$	937
Operating cash flows from financing leases		82		72		33
Financing cash flows from financing leases		686		687		442
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		6,480		498		1,829
Right-of-use assets obtained in exchange for finance lease obligations		2,074		46		2,069

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2021		2020
Operating Leases
Right-of-use assets	$	9,056	$	4,461
Lease liabilities:
Current lease liabilities		2,181		1,125
Non-current lease liabilities		7,202		3,591
Total operating lease liabilities	$	9,383	$	4,716


Finance Leases
Right-of-use assets	$	2,493	$	1,312
Lease liabilities:
Current lease liabilities		939		517
Non-current lease liabilities		1,952		895
Total finance lease liabilities	$	2,891	$	1,412


Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.26 years			4.45 years
Weighted-average remaining lease term—finance leases	2.21 years			2.67 years

Weighted Average Discount Rate
Weighted-average discount rate—operating leases		3.90	%		4.28	%
Weighted-average discount rate—finance leases		3.57	%		4.35	%

As of December 31, 2021, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2022		815			2,494
2023		946			1,775
2024		1,275			1,807
2025		—			1,442
2026		—			1,215
Thereafter		—			1,592
Total minimum lease payments		3,036			10,325
Less: imputed interest		(145	)		(942	)
Present value of lease liabilities	$	2,891		$	9,383

In January 2022, we entered into an operating lease for warehouse space, which is scheduled to commence during the first quarter of 2022. The agreement stipulates escalating fixed rent payments aggregating $7,154 to be paid over a lease term of 124 months.

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

11. INCOME TAXES:

Income (loss) before income tax expense consists of the following:


	Years Ended December 31,
	2021			2020			2019
United States	$	(60,500	)	$	(47,995	)	$	3,106
Foreign		51,208			44,471			18,225
	$	(9,292	)	$	(3,524	)	$	21,331

The components of income tax expense are as follows:


	Years Ended December 31,
	2021			2020			2019
Current
Federal	$	—		$	—		$	—
State		163			(106	)		1,033
Foreign		12,517			11,896			5,099
		12,680			11,790			6,132
Deferred
Federal		(10,318	)		(20,946	)		3,568
State		(965	)		(1,053	)		125
Foreign		(151	)		(410	)		(697	)
		(11,434	)		(22,409	)		2,996
Increase (decrease) in valuation allowance		12,460			22,017			(4,453	)
		1,026			(392	)		(1,457	)
Total income tax expense	$	13,706		$	11,398		$	4,675

For the years ended December 31, 2021, 2020, and 2019 we recorded foreign income tax expense of $13,543, $12,185, and $4,607, respectively.

The Tax Cuts and Jobs Act imposed a U.S. tax on GILTI that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. The Company has made a policy election related to its treatment of GILTI and will treat it as a current period expense in the reporting period in which the tax is incurred.

Final GILTI regulations were released in 2020. Among the changes was a GILTI “High-Tax Exception,” which allows foreign income deemed taxed at a sufficient effective rate to be excluded from a US owner’s GILTI income. All foreign income in 2021 and 2020 fell under this exception. It is expected that foreign income will continue to qualify for the exception in future years.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2021, 2020, and 2019 is as follows:


	2021				2020				2019
Statutory U.S. federal income tax rate		21.0		%		21.0		%		21.0		%
GILTI tax		—				—				16.9
Nondeductible executive compensation		(6.1	)			(0.9	)			0.4
Impact of share-based payment awards		(3.3	)			(12.4	)			(5.3	)
Tax effect of foreign items		(30.8	)			(70.7	)			4.5
State income taxes, net of federal benefit		6.8				26.0				4.0
U.S. and foreign tax credits		2.5				34.9				(1.1	)
Nondeductible transaction costs		-				(2.8	)			1.6
Nondeductible expenses and other		(4.0	)			(2.6	)			0.4
NOL adjustment due to change in GILTI regulations		—				308.9				—
Change in valuation allowance, federal and state		(133.6	)			(624.8	)			(20.5	)
Effective tax rate		(147.5	)	%		(323.4	)	%		21.9		%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2021 and 2020 are as follows:


	2021			2020
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	44,191		$	31,701
Inventories		4,642			1,593
Capitalized research and development costs		453			746
Accruals and reserves currently not deductible		3,245			3,200
Acquired intangible assets		(3,117	)		(3,870	)
Depreciation and amortization		(8,536	)		(2,804	)
Right-of-use assets		(2,777	)		(2,415	)
Lease liabilities		2,957			2,524
Stock-based compensation		1,891			1,354
Tax credit carryforwards		3,855			3,354
Net deferred tax asset		46,804			35,383
Valuation allowance		(49,038	)		(36,578	)
Net deferred tax liability	$	(2,234	)	$	(1,195	)

In assessing the realizability of our deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2021 and 2020 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2021, 2020, and 2019.

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2022 - 2032	$	38,444
2033 - 2037		26,631
Non-Expiring		122,920
	$	187,995

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. We do not believe that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. We continue to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs.

In January 2022, approximately $65,000 was repatriated from our Canadian subsidiary as a one-time event. It is still our intention to continue to permanently reinvest the historical undistributed earnings of our foreign subsidiary to the extent that we will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary as of December 31, 2021.

As of December 31, 2021, our gross unrecognized tax benefits totaled $805, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2021, 2020, and 2019. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2021.

A reconciliation of our unrecognized tax benefits is as follows:


	2021			2020			2019
Balance as of January 1	$	1,172		$	1,308		$	1,676
Additions for tax positions of prior periods		1			1			4
Reductions for tax positions of prior periods		(368	)		(137	)		(372	)
Balance as of December 31	$	805		$	1,172		$	1,308

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Stockholders' Equity

12. STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2021, 4,613 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2021			2020			2019
Risk-free interest rate(1)		0.47	%		1.33	%		2.52	%
Expected dividend yield		—			—			—
Expected stock price volatility(2)		50	%		42	%		41	%
Expected life of stock options (in years)(2)		4			5			5

(1)

Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

(2)

Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2021, 2020 and 2019 was $6.14, $2.79 and $5.19, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2021			2020			2019
Total compensation cost during the year	$	1,063		$	892		$	1,161
Amounts capitalized into inventory during the year		(538	)		(466	)		(343	)
Amounts recognized in cost of products sold for amounts previously capitalized		502			360			405
Amounts charged against income	$	1,027		$	786		$	1,223

The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $130, $3,117, and $92, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2021		1,232		$	10.12
Granted		366			13.68
Exercised		(33	)		7.50
Expired		(88	)		15.80
Forfeited		(67	)		10.67
Outstanding on December 31, 2021		1,410		$	10.73		6.88	$	1,113
Vested or expected to vest as of December 31, 2021		1,378		$	10.68		6.84	$	1,081
Exercisable on December 31, 2021		786		$	10.39		5.43	$	729

As of December 31, 2021, there was $2,571 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.8 years.

Net cash proceeds from the exercise of stock options were $246, $3,222 and $196 for the years ended December 31, 2021, 2020 and 2019, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2021:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37-$8.24		588		6.7	$	6.92		353	$	6.75
$8.87-$13.31		437		6.4		10.59		282		10.67
$14.95-$22.43		385		7.8		16.70		151		18.37
		1,410		6.9	$	10.73		786	$	10.39

The Stock Plan also permits us to grant restricted shares and restricted units of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the vesting restrictions lapse. Compensation cost of $4,094 $4,094 and $2,979 related to restricted shares was recognized during the years ended December 31, 2021, 2020 and 2019, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2021		659		$	9.95
Granted		454			13.23
Vested		(328	)		10.84
Forfeited		(84	)		11.02
Issued and unvested, December 31, 2021		701		$	11.53
Issued and expected to vest, December 31, 2021		638		$	11.32

As of December 31, 2021, there was $4,640 of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.9 years.

In connection with the vesting of restricted shares during the years ended December 31, 2021, 2020 and 2019, we purchased and immediately retired 107, 127 and 76 shares with aggregate values of $1,417, $1,219 and $949, respectively, in satisfaction of minimum tax withholding and exercise obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Prior to 2021, performance during the one-year period was based on a one-year income before tax target. Performance during the three-year period was based on achievement of a three-year compound annual growth rate for consolidated revenues. In 2021, performance shares were granted based on the achievement of three-year cumulative revenue metrics with a market-based condition, or a total shareholder return modifier. PSUs are converted into shares of our common stock once vested and the number of shares actually earned at the end of the performance period will vary, based on actual performance, from 0% to 200% of the target number of performance share units granted. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $2,650, $2,153 and $(83) related to the PSUs was recognized during the years ended December 31, 2021, 2020 and 2019, respectively.

The following table summarizes PSU activity under the Stock Plan:


	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2021		651		$	11.30
Granted (1)		182			10.99
Performance adjustment (2)		41		N/A
Vested		(123	)		16.66
Forfeited		(129	)		14.28
Issued and unvested, December 31, 2021		622		$	9.88
Issued and expected to vest, December 31, 2021		470		$	9.56

(1) Grant activity for all PSUs disclosed at target.

(2) Reflects the performance adjustment based on actual performance measured at the end of the performance period.

As of December 31, 2021, there was $2,349 of unrecognized compensation expense related to unvested performance stock units that is expected to be recognized over a weighted average period of 1.8 years.

In connection with the vesting of performance stock units during the year ended December 31, 2021, 2020 and 2019, we purchased and immediately retired 46, 121, and 213 shares with aggregate values of $696, $869 and $2,763, respectively.

Public Offering

On June 1, 2020, we entered into an underwriting agreement with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group LLC, as representatives of several underwriters, relating to the issuance and sale of 8,000 shares of our common stock. The price to the public in the offering was $11.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,200 shares of common stock. On June 3, 2020, we announced the full exercise by the underwriters of their option to purchase these additional shares.

The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-228877) we had previously filed with the SEC, and a prospectus supplement thereunder. The net proceeds from the offering were approximately $95,000 after deducting underwriting discounts and offering expenses paid by the Company.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2021, 2020, and 2019.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Transition Costs	12 Months Ended
Transition Costs	Dec. 31, 2021
Transition Costs [Abstract]
Transition Costs	13. TRANSITION COSTS On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a Transition Agreement providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Under the Transition Agreement, Dr. Tang’s service to the Company in all capacities is expected to end on March 31, 2022. Pursuant to the Transition Agreement, as of December 31, 2021, a severance accrual of $1,569 is included in the consolidated financial statements.

Business Segment Information

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Business Segment Information

14. BUSINESS SEGMENT INFORMATION:

Our business consists of two segments, which are described in Note 1: our “Diagnostics” segment and our “Molecular Solutions” segment.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the years ended December 31, 2021, 2020, and 2019, and asset information as of December 31, 2021 and 2020:


	Years ended December 31,
	2021			2020			2019
Net revenues:
Diagnostics	$	90,040		$	65,240		$	78,225
Molecular Solutions		143,634			106,481			76,380
Total	$	233,674		$	171,721		$	154,605
Operating income (loss):
Diagnostics	$	(57,177	)	$	(43,156	)	$	154
Molecular Solutions		47,013			37,979			18,457
Total	$	(10,164	)	$	(5,177	)	$	18,611
Depreciation and amortization:
Diagnostics	$	4,325		$	3,345		$	3,039
Molecular Solutions		7,333			6,042			4,300
Total	$	11,658		$	9,387		$	7,339
Capital expenditures:
Diagnostics(1)	$	26,994		$	17,860		$	6,073
Molecular Solutions		9,628			8,814			3,241
Total	$	36,622		$	26,674		$	9,314

(1) Excludes $11,495 for purchases of property and equipment under government contracts for the year ended December 31, 2021.


	December 31,
	2021		2020
Total assets:
Diagnostics	$	209,674	$	242,613
Molecular Solutions		251,316		211,859
Total	$	460,990	$	454,472

The following table represents total long-lived assets by geographic area:


	December 31,
	2021		2020
United States	$	76,232	$	36,897
Canada		11,003		10,616
Other regions		929		4,347
	$	88,164	$	51,860

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. COMMITMENTS AND CONTINGENCIES:

Purchase Commitments

As of December 31, 2021, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:


2022		36,721
2023		25,429
2024		16,934
2025		8,667
2026		—
	$	87,751

Additionally, we have entered into manufacturing agreements with certain third party vendors, in which minimum purchase commitments are required. If the minimum commitments are not achieved, we will be required to make annual penalty payments over

the next three years. Based on current forecasts, these penalties aggregate to approximately $2,209 for the three-year period. These estimated penalties can fluctuate based on changes in forecasted demand.

Employment Agreements

Under terms of employment agreements with certain employees, which extend through 2024, we are required to pay each individual a base salary for continuing employment with us as follows:


2022	$	2,911
2023		821
2024		426
2025		—
2026		—
	$	4,158

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on our future financial position or results of operations.

Spectrum Patent Litigation

In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation. We believe Spectrum's counterclaims are without merit and we filed a motion to dismiss both claims in October 2021. We are seeking injunctive relief and damages in this matter. On January 10, 2022, the Court assigned a new judge to preside over the matter, which vacated all dates for the trial. Spectrum filed their reply to our motion to dismiss on January 11, 2022. Though all other dates are pending, the Court has set the hearing for the motion to dismiss for March 30, 2022.

Retirement Plans

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Retirement Plans

16. RETIREMENT PLANS:

Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $1,295, $994 and $754 to the 401(k) Plan, net of forfeitures, in 2021, 2020, and 2019, respectively.

In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2021 and 2020, the value of the assets associated with this plan was $1,763 and $2,565, respectively, and is included in current assets and other assets in our consolidated balance sheets. Our obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in our consolidated balance sheets. As of December 31, 2021 and 2020, our total obligation under this plan was $1,763 and $2,565, respectively.

Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $4 per year. We contributed $448, $366 and $184 to the RRSP in 2021, 2020, and 2019, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Employee Retention Credit

Supplemental Cash Flow Information

In 2021, 2020 and 2019, we paid income taxes of $13,727, $9,263 and $10,611, respectively.

As of December 31, 2021, 2020 and 2019, we had accruals for purchases of property and equipment of $8,166 $802, and $660, respectively.

Investments

The following is a summary of our available-for-sale securities as of December 31, 2021 and 2020:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2021
Guaranteed investment certificates	$	33,249	$	—	$	—		$	33,249
Corporate bonds		20,473		—		(434	)		20,039
Total available-for-sale securities	$	53,722	$	—	$	(434	)	$	53,288
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At December 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	36,386	$	—	$	(107	)	$	36,279
Greater than one year	$	17,336	$	—	$	(327	)	$	17,009

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following table represents the change in contingent consideration:


Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

Accounts Receivable

Inventories

Property, Plant and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenue

Product Sales

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Service Revenues

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. We recognize revenues when we satisfy our performance obligations for services rendered.

Arrangements with Multiple-performance Obligations

Other Revenues

Deferred Revenue

Financing and Payment

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical Expedients and Exemptions

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:


	Years ended December 31,
	2021		2020		2019
Infectious disease testing	$	54,645	$	54,227	$	58,016
Risk assessment testing		9,678		9,194		12,189
Cryosurgical systems		-		-		7,054
Genomics (1)		63,350		36,878		56,200
Microbiome (1)		7,944		5,474		7,172
COVID-19 (1)		76,874		50,927		-
Laboratory services		11,840		8,746		6,767
Other product and service revenues		2,566		935		675
Net product and services revenues		226,897		166,381		148,073
Royalty income		4,420		3,432		5,116
Other non-product revenues		2,357		1,908		1,416
Other revenues		6,777		5,340		6,532
Net revenues	$	233,674	$	171,721	$	154,605

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	Years ended December 31,
	2021		2020		2019
United States	$	188,383	$	130,835	$	107,279
Europe		13,799		12,068		11,752
Other regions		31,492		28,818		35,574
	$	233,674	$	171,721	$	154,605

Customer and Vendor Concentrations

Business Combinations and Contingent Consideration

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:

•

future expected cash flows from sales and acquired developed technologies;

•

the probability of meeting the future events; and

•

discount rates used to determine the present value of estimated future cash flows.

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2021, 2020, and 2019, we incurred $5,103, $1,126, and $468, respectively, in advertising expenses.

Stock-Based Compensation

Income Taxes

Foreign Currency Translation

Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Years ended December 31,
	2021			2020			2019

Net income (loss)	$	(22,998	)	$	(14,922	)	$	16,656
Weighted-average shares of common stock outstanding:
Basic		71,981			67,505			61,675
Dilutive effect of stock options, restricted stock, and performance stock units		—			—			495
Diluted		71,981			67,505			62,170
Earnings (loss) per share:
Basic	$	(0.32	)	$	(0.22	)	$	0.27
Diluted	$	(0.32	)	$	(0.22	)	$	0.27

Accumulated Other Comprehensive Loss

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of December 31, 2021 and 2020:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2021
Guaranteed investment certificates	$	33,249	$	—	$	—		$	33,249
Corporate bonds		20,473		—		(434	)		20,039
Total available-for-sale securities	$	53,722	$	—	$	(434	)	$	53,288
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At December 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	36,386	$	—	$	(107	)	$	36,279
Greater than one year	$	17,336	$	—	$	(327	)	$	17,009

Summary of Change in Contingent Consideration

The following table represents the change in contingent consideration:


Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:


	Years ended December 31,
	2021		2020		2019
Infectious disease testing	$	54,645	$	54,227	$	58,016
Risk assessment testing		9,678		9,194		12,189
Cryosurgical systems		-		-		7,054
Genomics (1)		63,350		36,878		56,200
Microbiome (1)		7,944		5,474		7,172
COVID-19 (1)		76,874		50,927		-
Laboratory services		11,840		8,746		6,767
Other product and service revenues		2,566		935		675
Net product and services revenues		226,897		166,381		148,073
Royalty income		4,420		3,432		5,116
Other non-product revenues		2,357		1,908		1,416
Other revenues		6,777		5,340		6,532
Net revenues	$	233,674	$	171,721	$	154,605

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	Years ended December 31,
	2021		2020		2019
United States	$	188,383	$	130,835	$	107,279
Europe		13,799		12,068		11,752
Other regions		31,492		28,818		35,574
	$	233,674	$	171,721	$	154,605

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Years ended December 31,
	2021			2020			2019

Net income (loss)	$	(22,998	)	$	(14,922	)	$	16,656
Weighted-average shares of common stock outstanding:
Basic		71,981			67,505			61,675
Dilutive effect of stock options, restricted stock, and performance stock units		—			—			495
Diluted		71,981			67,505			62,170
Earnings (loss) per share:
Basic	$	(0.32	)	$	(0.22	)	$	0.27
Diluted	$	(0.32	)	$	(0.22	)	$	0.27

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Change in Contingent Consideration

The following table represents the change in contingent consideration:


Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

Summary of Unaudited Pro Forma Financial Information


	Year Ended December 31,
	2020			2019

Revenue	$	172,563		$	159,632
Net income (loss)		(14,937	)		16,261
Net income (loss) per share, basic		(0.22	)		0.26
Net income (loss) per share, diluted		(0.22	)		0.26

UrSure Inc [Member]

Summary of Change in Contingent Consideration

The following table represents the change in contingent consideration:


Estimated fair value of contingent consideration as of acquisition date	$	3,440
Change in fair value during the period		(989	)
Balance as of December 31, 2020		2,451
Payments made during the period		(406	)
Change in fair value during the period		(1,485	)
Balance as of December 31, 2021	$	560

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,600
Goodwill		3,586
Total assets acquired		7,501
Liabilities Assumed
Current liabilities		335
Deferred tax liability		689
Total liabilities assumed		1,024
Net Assets Acquired		6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

Diversigen, Inc. [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,458
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,458

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

Corebiome Inc. and Novosanis NV [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:


	Estimated Useful
Description	Life (in years)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Government Capital Contracts (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Government Contracts Balance Included in Consolidated Balance Sheet

The balances corresponding to government contracts included in our consolidated balance sheet as of December 31, 2021, are as follows:


	December 31, 2021
Other current assets:
Billed receivables	$	9,913
Unbilled receivables		9,716
Total other current assets		19,629
Property, plant and equipment, net:
Cost of assets		11,495
Reduction for funding earned, not yet received		(10,964	)
Reduction for funding received		(531	)
Total property, plant and equipment, net		-
Accrued expenses and other current liabilities		(8,103	)

Inventories (Tables)

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,
	2021		2020
Raw materials	$	33,168	$	15,425
Work in process		2,252		2,572
Finished goods		17,718		13,866
	$	53,138	$	31,863

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment


	December 31,
	2021			2020
Land	$	1,118		$	1,118
Buildings and improvements		35,420			26,480
Machinery and equipment		57,919			36,878
Computer equipment and software		14,700			13,024
Furniture and fixtures		4,228			3,545
Construction in progress		35,936			24,419
		149,321			105,464
Less accumulated depreciation		(61,157	)		(53,604	)
	$	88,164		$	51,860

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table represents total goodwill by operating segment:


	December 31,
	2021		2020
Diagnostics	$	3,604	$	3,586
Molecular Solutions		36,675		36,765
	$	40,279	$	40,351

The changes in goodwill are as follows:


	December 31,
	2021			2020
Balance as of January 1		40,351			36,201
Goodwill acquired during the year		—			3,586
Purchase price adjustment		18			(126	)
Change related to foreign currency translation		(90	)		690
Balance as of December 31	$	40,279		$	40,351

Summary of Intangible Assets

Intangible assets consist of the following:


			December 31, 2021
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	15,016	$	(11,205	)	$	3,811
Patents and product rights		5		7,785		(6,241	)		1,544
Developed technology	7-10			16,293		(9,725	)		6,568
Tradename	5-15			5,661		(3,241	)		2,420
			$	44,755	$	(30,412	)	$	14,343


			December 31, 2020
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	14,997	$	(9,685	)	$	5,312
Patents and product rights		5		7,766		(5,792	)		1,974
Developed technology	7-10			16,603		(8,880	)		7,723
Tradename	5-15			5,645		(2,750	)		2,895
			$	45,011	$	(27,107	)	$	17,904

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2022		2,305
2023		2,305
2024		2,265
2025		2,012
2026		1,630
Beyond		3,826
	$	14,343

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Schedule of Accrued Expenses


	December 31,
	2021		2020
Payroll and related benefits	$	15,570	$	14,769
Commitment to purchase under government contract		8,103		—
Professional fees		3,335		978
Sales tax payable		2,227		2,400
Other		4,543		4,080
	$	33,778	$	22,227

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:


	Years ended December 31,
	2021		2020		2019
Operating lease cost	$	2,226	$	1,291	$	964
Variable lease cost		201		—		—
Finance lease cost:
Amortization of right-of use assets		900		627		410
Interest on lease liabilities		82		72		36
Total finance lease cost		982		699		446
Total lease cost	$	3,409	$	1,990	$	1,410

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:


	Years ended December 31,
	2021		2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,733	$	1,280	$	937
Operating cash flows from financing leases		82		72		33
Financing cash flows from financing leases		686		687		442
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		6,480		498		1,829
Right-of-use assets obtained in exchange for finance lease obligations		2,074		46		2,069

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2021		2020
Operating Leases
Right-of-use assets	$	9,056	$	4,461
Lease liabilities:
Current lease liabilities		2,181		1,125
Non-current lease liabilities		7,202		3,591
Total operating lease liabilities	$	9,383	$	4,716


Finance Leases
Right-of-use assets	$	2,493	$	1,312
Lease liabilities:
Current lease liabilities		939		517
Non-current lease liabilities		1,952		895
Total finance lease liabilities	$	2,891	$	1,412

Summary of Lease Term and Discount Rate


Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5.26 years			4.45 years
Weighted-average remaining lease term—finance leases	2.21 years			2.67 years

Weighted Average Discount Rate
Weighted-average discount rate—operating leases		3.90	%		4.28	%
Weighted-average discount rate—finance leases		3.57	%		4.35	%

Schedule of Minimum Lease Payments by Period Expected

As of December 31, 2021, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2022		815			2,494
2023		946			1,775
2024		1,275			1,807
2025		—			1,442
2026		—			1,215
Thereafter		—			1,592
Total minimum lease payments		3,036			10,325
Less: imputed interest		(145	)		(942	)
Present value of lease liabilities	$	2,891		$	9,383

In January 2022, we entered into an

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense consists of the following:


	Years Ended December 31,
	2021			2020			2019
United States	$	(60,500	)	$	(47,995	)	$	3,106
Foreign		51,208			44,471			18,225
	$	(9,292	)	$	(3,524	)	$	21,331

Components of Income Tax Expense (Benefit)

The components of income tax expense are as follows:


	Years Ended December 31,
	2021			2020			2019
Current
Federal	$	—		$	—		$	—
State		163			(106	)		1,033
Foreign		12,517			11,896			5,099
		12,680			11,790			6,132
Deferred
Federal		(10,318	)		(20,946	)		3,568
State		(965	)		(1,053	)		125
Foreign		(151	)		(410	)		(697	)
		(11,434	)		(22,409	)		2,996
Increase (decrease) in valuation allowance		12,460			22,017			(4,453	)
		1,026			(392	)		(1,457	)
Total income tax expense	$	13,706		$	11,398		$	4,675

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2021, 2020, and 2019 is as follows:


	2021				2020				2019
Statutory U.S. federal income tax rate		21.0		%		21.0		%		21.0		%
GILTI tax		—				—				16.9
Nondeductible executive compensation		(6.1	)			(0.9	)			0.4
Impact of share-based payment awards		(3.3	)			(12.4	)			(5.3	)
Tax effect of foreign items		(30.8	)			(70.7	)			4.5
State income taxes, net of federal benefit		6.8				26.0				4.0
U.S. and foreign tax credits		2.5				34.9				(1.1	)
Nondeductible transaction costs		-				(2.8	)			1.6
Nondeductible expenses and other		(4.0	)			(2.6	)			0.4
NOL adjustment due to change in GILTI regulations		—				308.9				—
Change in valuation allowance, federal and state		(133.6	)			(624.8	)			(20.5	)
Effective tax rate		(147.5	)	%		(323.4	)	%		21.9		%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2021 and 2020 are as follows:


	2021			2020
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	44,191		$	31,701
Inventories		4,642			1,593
Capitalized research and development costs		453			746
Accruals and reserves currently not deductible		3,245			3,200
Acquired intangible assets		(3,117	)		(3,870	)
Depreciation and amortization		(8,536	)		(2,804	)
Right-of-use assets		(2,777	)		(2,415	)
Lease liabilities		2,957			2,524
Stock-based compensation		1,891			1,354
Tax credit carryforwards		3,855			3,354
Net deferred tax asset		46,804			35,383
Valuation allowance		(49,038	)		(36,578	)
Net deferred tax liability	$	(2,234	)	$	(1,195	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2022 - 2032	$	38,444
2033 - 2037		26,631
Non-Expiring		122,920
	$	187,995

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:


	2021			2020			2019
Balance as of January 1	$	1,172		$	1,308		$	1,676
Additions for tax positions of prior periods		1			1			4
Reductions for tax positions of prior periods		(368	)		(137	)		(372	)
Balance as of December 31	$	805		$	1,172		$	1,308

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2021			2020			2019
Risk-free interest rate(1)		0.47	%		1.33	%		2.52	%
Expected dividend yield		—			—			—
Expected stock price volatility(2)		50	%		42	%		41	%
Expected life of stock options (in years)(2)		4			5			5

(1)

Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

(2)

Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2021			2020			2019
Total compensation cost during the year	$	1,063		$	892		$	1,161
Amounts capitalized into inventory during the year		(538	)		(466	)		(343	)
Amounts recognized in cost of products sold for amounts previously capitalized		502			360			405
Amounts charged against income	$	1,027		$	786		$	1,223

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2021		1,232		$	10.12
Granted		366			13.68
Exercised		(33	)		7.50
Expired		(88	)		15.80
Forfeited		(67	)		10.67
Outstanding on December 31, 2021		1,410		$	10.73		6.88	$	1,113
Vested or expected to vest as of December 31, 2021		1,378		$	10.68		6.84	$	1,081
Exercisable on December 31, 2021		786		$	10.39		5.43	$	729

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2021:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37-$8.24		588		6.7	$	6.92		353	$	6.75
$8.87-$13.31		437		6.4		10.59		282		10.67
$14.95-$22.43		385		7.8		16.70		151		18.37
		1,410		6.9	$	10.73		786	$	10.39

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2021		659		$	9.95
Granted		454			13.23
Vested		(328	)		10.84
Forfeited		(84	)		11.02
Issued and unvested, December 31, 2021		701		$	11.53
Issued and expected to vest, December 31, 2021		638		$	11.32

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:


	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2021		651		$	11.30
Granted (1)		182			10.99
Performance adjustment (2)		41		N/A
Vested		(123	)		16.66
Forfeited		(129	)		14.28
Issued and unvested, December 31, 2021		622		$	9.88
Issued and expected to vest, December 31, 2021		470		$	9.56

(1) Grant activity for all PSUs disclosed at target.

(2) Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2021, 2020, and 2019, and asset information as of December 31, 2021 and 2020:


	Years ended December 31,
	2021			2020			2019
Net revenues:
Diagnostics	$	90,040		$	65,240		$	78,225
Molecular Solutions		143,634			106,481			76,380
Total	$	233,674		$	171,721		$	154,605
Operating income (loss):
Diagnostics	$	(57,177	)	$	(43,156	)	$	154
Molecular Solutions		47,013			37,979			18,457
Total	$	(10,164	)	$	(5,177	)	$	18,611
Depreciation and amortization:
Diagnostics	$	4,325		$	3,345		$	3,039
Molecular Solutions		7,333			6,042			4,300
Total	$	11,658		$	9,387		$	7,339
Capital expenditures:
Diagnostics(1)	$	26,994		$	17,860		$	6,073
Molecular Solutions		9,628			8,814			3,241
Total	$	36,622		$	26,674		$	9,314

(1) Excludes $11,495 for purchases of property and equipment under government contracts for the year ended December 31, 2021.


	December 31,
	2021		2020
Total assets:
Diagnostics	$	209,674	$	242,613
Molecular Solutions		251,316		211,859
Total	$	460,990	$	454,472

Presentation of Total Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:


	December 31,
	2021		2020
United States	$	76,232	$	36,897
Canada		11,003		10,616
Other regions		929		4,347
	$	88,164	$	51,860

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Schedule of Outstanding Non-cancelable Purchase Commitments

As of December 31, 2021, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:


2022		36,721
2023		25,429
2024		16,934
2025		8,667
2026		—
	$	87,751

Schedule of Base Salary for Continuing Employment Agreement

Under terms of employment agreements with certain employees, which extend through 2024, we are required to pay each individual a base salary for continuing employment with us as follows:


2022	$	2,911
2023		821
2024		426
2025		—
2026		—
	$	4,158

The Company - Additional Information (Detail)	12 Months Ended
The Company - Additional Information (Detail)	Dec. 31, 2021 Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid	$ 13,727	$ 9,263	$ 10,611
Increase or decrease in allowance for doubtful accounts	(253)	941	2,248
Write-offs against allowance for doubtful accounts	115	501	110
Accruals for purchases of property and equipment	8,166	802	660
Provision for expected credit losses for available-for-sale securities	98
Cash and cash equivalents	116,762	160,802
Fair value of plan assets	1,763	2,565
Deferred revenue	$ 2,936	4,811
Contract with customer payment terms, description	Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Advertising expenses	$ 5,103	1,126	468
Net foreign exchange (losses) gains	(667)	(337)	$ (1,339)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	9,643	8,749
Unrealized loss on marketable securities	434	348
Long-term Contract [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	1,093	1,595
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 1,160	$ 71,489
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	769	984	768
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,843	$ 3,216
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk		11.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk			15.00%
Cost of Products and Service Sold [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit	2,536
Research and Development [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit	1,134
Sales and Marketing [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit	924
General and Administrative Costs [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit	$ 1,134
Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Minimum [Member] \| Computer Equipment and Software [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Contract with customer payment terms	120 days
Sales commissions amortization period	1 year
Maximum [Member] \| Computer Equipment and Software [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Internal Revenue Service (IRS) [Member] \| Other Current Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount due from Internal Revenue Services	$ 5,728

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 53,722	$ 96,665
Gross Unrealized Gains		135
Gross Unrealized Losses	(434)	(483)
Fair Value	53,288	96,317
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	33,249	25,132
Fair Value	33,249	25,132
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,473	71,533
Gross Unrealized Gains		135
Gross Unrealized Losses	(434)	(483)
Fair Value	20,039	$ 71,185
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	36,386
Gross Unrealized Losses	(107)
Fair Value	36,279
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	17,336
Gross Unrealized Losses	(327)
Fair Value	$ 17,009

Summary of Significant Accounting Policies - Summary of Change in Contingent Consideration (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Combination, Contingent Consideration Arrangements [Abstract]
Beginning Balance	$ 2,451	$ 3,612
Addition related to acquisition (initial measurement)		3,440	$ 4,350
Payments made during the period	(406)	(3,500)
Change in the estimated fair value of acquisition-related contingent consideration	(1,485)	(1,099)	(664)
Currency translation adjustment		(2)	(74)
Ending Balance	$ 560	$ 2,451	$ 3,612

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Net revenues	$ 233,674	$ 171,721	$ 154,605
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	226,897	166,381	148,073
Product and Services Revenues [Member] \| Infectious Disease Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	54,645	54,227	58,016
Product and Services Revenues [Member] \| Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,678	9,194	12,189
Product and Services Revenues [Member] \| Cryosurgical Systems [Member]
Disaggregation Of Revenue [Line Items]
Net revenues			7,054
Product and Services Revenues [Member] \| Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	63,350	36,878	56,200
Product and Services Revenues [Member] \| Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	7,944	5,474	7,172
Product and Services Revenues [Member] \| COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	76,874	50,927
Product and Services Revenues [Member] \| Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,840	8,746	6,767
Product and Services Revenues [Member] \| Other Product And Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,566	935	675
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	6,777	5,340	6,532
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,420	3,432	5,116
Other [Member] \| Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 2,357	$ 1,908	$ 1,416

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenues	$ 233,674	$ 171,721	$ 154,605
Product and Services Revenues [Member]
Disaggregation of Revenue [Line Items]
Net revenues	226,897	166,381	148,073
Product and Services Revenues [Member] \| Genomics [Member]
Disaggregation of Revenue [Line Items]
Net revenues	63,350	36,878	56,200
Product and Services Revenues [Member] \| Genomics [Member] \| Reclassification, Adjustment [Member]
Disaggregation of Revenue [Line Items]
Net revenues		(263)
Product and Services Revenues [Member] \| Microbiome [Member]
Disaggregation of Revenue [Line Items]
Net revenues	7,944	5,474	$ 7,172
Product and Services Revenues [Member] \| Microbiome [Member] \| Reclassification, Adjustment [Member]
Disaggregation of Revenue [Line Items]
Net revenues		(682)
Product and Services Revenues [Member] \| C O V I D19 [Member]
Disaggregation of Revenue [Line Items]
Net revenues	$ 76,874	50,927
Product and Services Revenues [Member] \| C O V I D19 [Member] \| Reclassification, Adjustment [Member]
Disaggregation of Revenue [Line Items]
Net revenues		$ 945

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Net revenues	$ 233,674	$ 171,721	$ 154,605
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	188,383	130,835	107,279
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	13,799	12,068	11,752
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 31,492	$ 28,818	$ 35,574

- Definition

+ References

+ Details

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ (22,998)	$ (14,922)	$ 16,656
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
Basic	71,981	67,505	61,675
Dilutive effect of stock options, restricted stock, and performance stock units			495
Diluted	71,981	67,505	62,170
Basic	$ (0.32)	$ (0.22)	$ 0.27
Diluted	$ (0.32)	$ (0.22)	$ 0.27

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands				3 Months Ended	12 Months Ended
	Jul. 22, 2020	Nov. 08, 2019	Jan. 04, 2019	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current					$ 354	$ 2,049
Net revenues					233,674	171,721	$ 154,605
Net income (loss)					$ (22,998)	(14,922)	16,656
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	3 years
Estimated fair value of contingent consideration	$ 3,440
Acquisition-related costs						393
UrSure Inc [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Purchase price		$ 12,000
Business acquisition contingent consideration, non-current						$ 1,500
Acquisition-related costs							1,198
Business combination contingent consideration expected payment year						2020
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price			$ 13,320
Business acquisition contingent consideration, non-current			$ 32,400
Business combination contingent consideration expected payment period			3 years			1 year
Estimated fair value of contingent consideration			$ 4,350			$ 0	3,612
Acquisition-related costs							$ 639
Payment of acquisition-related contingent consideration			$ 3,500	$ 3,500
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)			10 years

Business Combinations - Summary of Change in Contingent Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition, Contingent Consideration [Line Items]
Beginning Balance	$ 2,451	$ 3,612
Payments made during the period	(406)	(3,500)
Change in fair value during the period	(1,485)	(1,099)	$ (664)
Ending Balance	560	2,451	$ 3,612
Ur Sure Inc [Member]
Business Acquisition, Contingent Consideration [Line Items]
Beginning Balance	2,451
Estimated fair value of contingent consideration as of acquisition date		3,440
Payments made during the period	(406)
Change in fair value during the period	(1,485)	(989)
Ending Balance	$ 560	$ 2,451

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jul. 22, 2020	Dec. 31, 2019	Nov. 08, 2019	Jan. 04, 2019
Assets Acquired
Goodwill	$ 40,279	$ 40,351		$ 36,201
UrSure Inc [Member]
Assets Acquired
Accounts receivable			$ 285
Other current assets			24
Other assets			6
Intangibles			3,600
Goodwill			3,586
Total assets acquired			7,501
Liabilities Assumed
Current liabilities			335
Deferred tax liability			689
Total liabilities assumed			1,024
Net Assets Acquired			6,477
Estimated fair value of contingent consideration			(3,440)
Net Cash Paid			$ 3,037
Diversigen, Inc. [Member]
Assets Acquired
Accounts receivable					$ 1,234
Other current assets					45
Property, plant, and equipment, net					1,916
Intangibles					3,560
Goodwill					6,317
Total assets acquired					13,072
Liabilities Assumed
Current liabilities					1,123
Deferred tax liability					598
Other long-term liabilities					893
Total liabilities assumed					2,614
Net Assets Acquired					10,458
Net Cash Paid					$ 10,458
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable						$ 791
Inventories						310
Other current assets						82
Property, plant, and equipment, net						414
Other assets						5
Intangibles						8,400
Goodwill						10,368
Total assets acquired						20,370
Liabilities Assumed
Current liabilities						1,180
Notes payable, short-term						730
Deferred tax liability						819
Other long-term liabilities						74
Total liabilities assumed						2,803
Net Assets Acquired						17,567
Estimated fair value of contingent consideration		$ 0		$ (3,612)		(4,350)
Net Cash Paid						$ 13,217

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands				12 Months Ended
	Jul. 22, 2020	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Net of cash acquired				$ 3,037	$ 23,801
UrSure Inc [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 111
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Net of cash acquired		$ 479
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Net of cash acquired			$ 103

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - USD ($) $ in Thousands			12 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2021	Dec. 31, 2020
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Estimated Useful Life			10 years	10 years
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 3,560
Diversigen, Inc. [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,900
Acquired intangibles, Estimated Useful Life	10 years
Diversigen, Inc. [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 660
Acquired intangibles, Estimated Useful Life	9 years
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 8,400
Corebiome Inc. and Novosanis NV [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 2,200
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 1,200
Acquired intangibles, Estimated Useful Life		8 years 4 months 2 days
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 5,000
Acquired intangibles, Estimated Useful Life		10 years

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - CoreBiome Inc. Diversign Novosanis NV and UrSure [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Revenue	$ 172,563	$ 159,632
Net income (loss)	$ (14,937)	$ 16,261
Net income (loss) per share, basic	$ (0.22)	$ 0.26
Net income (loss) per share, diluted	$ (0.22)	$ 0.26

Sale of Cryosurgical Business - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Aug. 16, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business	$ 10,149
Proceeds from sale of business	12,000
Cryosurgical Systems [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Consideration receivable from sale of business		$ 12,000
Gain on sale of business	10,149
Proceeds from sale of business	$ 12,000

Government Capital Contracts (Additional Information) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount					$ 109,000
Proceeds from funding under government contract		$ 531
Percentage withheld under government contracts subject to validation testing		15.00%
Net revenues		$ 233,674	$ 171,721	$ 154,605
Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from funding under government contract	$ 15,428
Other Income [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		6,777	$ 5,340	$ 6,532
Other Income [Member] \| Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		$ 561

- Definition

+ References

+ Details

Government Capital Contracts - Summary of Government Contracts Balance Included in Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other current assets:
Total other current assets	$ 28,990	$ 4,934
Property, plant and equipment, net:
Cost of assets	149,321	105,464
Property plant and equipment Net	88,164	51,860
Accrued expenses and other current liabilities	33,778	$ 22,227
Government Contract [Member]
Other current assets:
Billed receivables	9,913
Unbilled receivables	9,716
Total other current assets	19,629
Property, plant and equipment, net:
Cost of assets	11,495
Reduction for funding earned, not yet received	(10,964)
Reduction for funding received	(531)
Property plant and equipment Net	0
Accrued expenses and other current liabilities	$ (8,103)

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory, Net [Abstract]
Raw materials	$ 33,168	$ 15,425
Work in process	2,252	2,572
Finished goods	17,718	13,866
Inventories	$ 53,138	$ 31,863

Inventories - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Inventory adjustments	$ 13,400	$ 2,564	$ 1,318
COVID-19 Antibody
Inventory [Line Items]
Inventory adjustments	$ 3,008

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 149,321	$ 105,464
Less accumulated depreciation	(61,157)	(53,604)
Property plant and equipment Net	88,164	51,860
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	35,420	26,480
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	57,919	36,878
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	14,700	13,024
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	4,228	3,545
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 35,936	$ 24,419

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 7,498	$ 5,514	$ 4,421

Goodwill and Other Intangible Assets - Schedule of Goodwill by Operating Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill	$ 40,279	$ 40,351	$ 36,201
Diagnostics [Member]
Goodwill [Line Items]
Goodwill	3,604	3,586
Molecular Solutions [Member]
Goodwill [Line Items]
Goodwill	$ 36,675	$ 36,765

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Beginning Balance	$ 40,351	$ 36,201
Goodwill acquired during the year		3,586
Purchase price adjustment	18	(126)
Change related to foreign currency translation	(90)	690
Ending Balance	$ 40,279	$ 40,351

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 44,755	$ 45,011
Intangible Assets, Accumulated Amortization	(30,412)	(27,107)
Intangible Assets, Net	$ 14,343	$ 17,904
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 15,016	$ 14,997
Intangible Assets, Accumulated Amortization	(11,205)	(9,685)
Intangible Assets, Net	$ 3,811	$ 5,312
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	5 years
Intangible Assets, Gross	$ 7,785	$ 7,766
Intangible Assets, Accumulated Amortization	(6,241)	(5,792)
Intangible Assets, Net	1,544	1,974
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	16,293	16,603
Intangible Assets, Accumulated Amortization	(9,725)	(8,880)
Intangible Assets, Net	$ 6,568	$ 7,723
Developed Technology [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Developed Technology [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 5,661	$ 5,645
Intangible Assets, Accumulated Amortization	(3,241)	(2,750)
Intangible Assets, Net	$ 2,420	$ 2,895
Tradename [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	5 years
Tradename [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 3,260	$ 3,246	$ 2,522

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022	$ 2,305
2023	2,305
2024	2,265
2025	2,012
2026	1,630
Beyond	3,826
Intangible Assets, Net	$ 14,343	$ 17,904

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 15,570	$ 14,769
Commitment to purchase under government contracts	8,103
Professional fees	3,335	978
Sales tax payable	2,227	2,400
Other	4,543	4,080
Accrued expenses, Total	$ 33,778	$ 22,227

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 31, 2022
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Aggregate ROU asset and offsetting lease liability	$ 2,074	$ 46	$ 2,069
Fixed rent payments to be paid over lease term	10,325
Leases in Purchase Commitment [Member]
Lessee Lease Description [Line Items]
Aggregate ROU asset and offsetting lease liability	$ 2,074
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years
Subsequent Event [Member]
Lessee Lease Description [Line Items]
Operating lease term				124 months
Subsequent Event [Member] \| New Warehouse Lease [Member]
Lessee Lease Description [Line Items]
Fixed rent payments to be paid over lease term				$ 7,154

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lease, Cost [Abstract]
Operating lease cost	$ 2,226	$ 1,291	$ 964
Variable lease cost	201
Finance Lease Cost
Amortization of right-of use assets	900	627	410
Interest on lease liabilities	82	72	36
Total finance lease cost	982	699	446
Total lease cost	$ 3,409	$ 1,990	$ 1,410

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 3,733	$ 1,280	$ 937
Operating cash flows from financing leases	82	72	33
Financing cash flows from financing leases	686	687	442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations	6,480	498	1,829
Right-of-use assets obtained in exchange for finance lease obligations	$ 2,074	$ 46	$ 2,069

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Leases
Right-of-use assets	$ 9,056	$ 4,461
Lease liabilities:
Current lease liabilities	2,181	1,125
Non-current lease liabilities	7,202	3,591
Total operating lease liabilities	9,383	4,716
Finance Leases
Right-of-use assets	2,493	1,312
Lease liabilities:
Current lease liabilities	939	517
Non-current lease liabilities	1,952	895
Total finance lease liabilities	$ 2,891	$ 1,412

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2021	Dec. 31, 2020
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	5 years 3 months 3 days	4 years 5 months 12 days
Weighted-average remaining lease term—finance leases	2 years 2 months 15 days	2 years 8 months 1 day
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	3.90%	4.28%
Weighted-average discount rate—finance leases	3.57%	4.35%

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finance Lease Liabilities, Payments, Due [Abstract]
2022	$ 815
2023	946
2024	1,275
Total minimum finance lease payments	3,036
Less: imputed interest	(145)
Present Value of Finance Lease Liabilities	2,891	$ 1,412
Operating Lease Liabilities, Payments Due [Abstract]
2022	2,494
2023	1,775
2024	1,807
2025	1,442
2026	1,215
Thereafter	1,592
Total Minimum Operating Lease Payments	10,325
Less: imputed interest	(942)
Present Value of Operating Lease Liabilities	$ 9,383	$ 4,716

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]
United States	$ (60,500)	$ (47,995)	$ 3,106
Foreign	51,208	44,471	18,225
Income (loss) before income taxes	$ (9,292)	$ (3,524)	$ 21,331

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current
Federal	$ 0	$ 0	$ 0
State	163,000	(106,000)	1,033,000
Foreign	12,517,000	11,896,000	5,099,000
Total current income tax expense (benefit)	12,680,000	11,790,000	6,132,000
Deferred
Federal	(10,318,000)	(20,946,000)	3,568,000
State	(965,000)	(1,053,000)	125,000
Foreign	(151,000)	(410,000)	(697,000)
Total deferred income tax expense (benefit)	(11,434,000)	(22,409,000)	2,996,000
Increase (decrease) in valuation allowance	12,460,000	22,017,000	(4,453,000)
Deferred income taxes	1,026,000	(392,000)	(1,457,000)
Total income tax expense	$ 13,706,000	$ 11,398,000	$ 4,675,000

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Contingency [Line Items]
Foreign income tax expense		$ 13,543,000	$ 12,185,000	$ 4,607,000
U.S. federal income tax benefits		0	0	0
Gross unrecognized tax benefits		$ 805,000	$ 1,172,000	$ 1,308,000	$ 1,676,000
Subsequent Event [Member]
Income Tax Contingency [Line Items]
Foreign earnings repatriated	$ 65,000,000

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
GILTI tax			16.90%
Nondeductible executive compensation	(6.10%)	(0.90%)	0.40%
Impact of share-based payment awards	(3.30%)	(12.40%)	(5.30%)
Tax effect of foreign items	(30.80%)	(70.70%)	4.50%
State income taxes, net of federal benefit	6.80%	26.00%	4.00%
U.S. and foreign tax credits	2.50%	34.90%	(1.10%)
Nondeductible transaction costs		(2.80%)	1.60%
Nondeductible expenses and other	(4.00%)	(2.60%)	0.40%
NOL adjustment due to change in GILTI regulations		308.90%
Change in valuation allowance, federal and state	(133.60%)	(624.80%)	(20.50%)
Effective tax rate	(147.50%)	(323.40%)	21.90%

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 44,191	$ 31,701
Inventories	4,642	1,593
Capitalized research and development costs	453	746
Accruals and reserves currently not deductible	3,245	3,200
Acquired intangible assets	(3,117)	(3,870)
Depreciation and amortization	(8,536)	(2,804)
Right-of-use assets	(2,777)	(2,415)
Lease liabilities	2,957	2,524
Stock-based compensation	1,891	1,354
Tax credit carryforwards	3,855	3,354
Net deferred tax asset	46,804	35,383
Valuation allowance	(49,038)	(36,578)
Net deferred tax liability	$ (2,234)	$ (1,195)

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 187,995
2022 - 2032 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	38,444
2033- 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	26,631
Non-Expiring [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 122,920

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 1,172	$ 1,308	$ 1,676
Additions for tax positions of prior periods	1	1	4
Reductions for tax positions of prior periods	(368)	(137)	(372)
Balance as of December 31	$ 805	$ 1,172	$ 1,308

Stockholders' Equity - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 01, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan		4,613,000
Amount share repurchase program of common shares					$ 25,000,000
Total cost of common stock purchased and retired		$ 2,113,000	$ 2,088,000	$ 3,712,000
Proceeds from exercise of stock options		246,000	3,222,000	196,000
Income tax benefit realized from stock option exercises during period		0	0	0
Total compensation cost		$ 7,807,000	$ 7,139,000	$ 4,057,000
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares	8,000,000
Public offering price per share	$ 11.00
Net offering proceeds after deducting underwriting discount and commission and offering expenses	$ 95,000,000
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters option exercisable period	30 days
Underwriters option to purchase additional shares	1,200,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price		75.00%
Granted exercise periods		10 years
Vesting period		4 years
Vesting of Options		Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted		$ 6.14	$ 2.79	$ 5.19
Aggregate intrinsic value of options exercised		$ 130,000	$ 3,117,000	$ 92,000
Unrecognized compensation expense related to unvested option awards		$ 2,571,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		2 years 9 months 18 days
Proceeds from exercise of stock options		$ 246,000	3,222,000	196,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 10 months 24 days
Total compensation cost		$ 4,094,000	$ 4,094,000	$ 2,979,000
Unrecognized compensation expense related to unvested restricted stock awards		$ 4,640,000
Vesting of restricted shares, withholding and exercise obligations		107,000	127,000	76,000
Restricted shares of common stock, aggregate values		$ 1,417,000	$ 1,219,000	$ 949,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		46,000	21,000	213,000
Total cost of common stock purchased and retired		$ 696,000	$ 869,000	$ 2,763,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 9 months 18 days
Total compensation cost		$ 2,650,000	$ 2,153,000	$ (83,000)
Unrecognized compensation expense related to unvested restricted stock awards		$ 2,349,000
Maximum [Member] \| Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted		200.00%
Minimum [Member] \| Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted		0.00%

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	0.47%	1.33%	2.52%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	50.00%	42.00%	41.00%
Expected life of stock options (in years)	4 years	5 years	5 years

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Total compensation cost during the year	$ 1,063	$ 892	$ 1,161
Amounts capitalized into inventory during the year	(538)	(466)	(343)
Amounts recognized in cost of products sold for amounts previously capitalized	502	360	405
Amounts charged against income	$ 1,027	$ 786	$ 1,223

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance \| shares	1,232
Options, Granted \| shares	366
Options, Exercised \| shares	(33)
Options, Expired \| shares	(88)
Options, Forfeited \| shares	(67)
Options, Outstanding, Ending Balance \| shares	1,410
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance \| $ / shares	$ 10.12
Options, Vested or expected to vest \| shares	1,378
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	$ 13.68
Options, Exercisable \| shares	786
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	$ 7.50
Weighted-Average Exercise Price Per Share, Expired \| $ / shares	15.80
Weighted-Average Exercise Price Per Share, Forfeited \| $ / shares	10.67
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance \| $ / shares	10.73
Weighted-Average Exercise Price Per Share, Vested or expected to vest \| $ / shares	10.68
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 10.39
Weighted-Average Remaining Contractual Term, Outstanding	6 years 10 months 17 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 10 months 2 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 5 months 4 days
Aggregate Intrinsic Value, Outstanding \| $	$ 1,113
Aggregate Intrinsic Value, Vested or expected to vest \| $	1,081
Aggregate Intrinsic Value, Exercisable \| $	$ 729

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	1,410
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.73
Number Exercisable, Options exercisable \| shares	786
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.39
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.37
Range of exercise prices, Upper Range Limit	$ 8.24
Number Outstanding, Options outstanding \| shares	588
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.92
Number Exercisable, Options exercisable \| shares	353
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.75
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.87
Range of exercise prices, Upper Range Limit	$ 13.31
Number Outstanding, Options outstanding \| shares	437
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.59
Number Exercisable, Options exercisable \| shares	282
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.67
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	14.95
Range of exercise prices, Upper Range Limit	$ 22.43
Number Outstanding, Options outstanding \| shares	385
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 9 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 16.70
Number Exercisable, Options exercisable \| shares	151
Weighted-Average Exercise Price Per Share, Options exercisable	$ 18.37

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance \| shares	659
Shares, Granted \| shares	454
Shares, Vested \| shares	(328)
Shares, Forfeited \| shares	(84)
Shares, Issued and unvested, Ending Balance \| shares	701
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 9.95
Shares, Issued and expected to vest \| shares	638
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	$ 13.23
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	10.84
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	11.02
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	11.53
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 11.32

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	651
Shares, Granted	182
Performance adjustment	41
Shares, Vested	(123)
Shares, Forfeited	(129)
Shares, Issued and unvested, Ending Balance	622
Shares, Issued and expected to vest	470
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 11.30
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	10.99
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	16.66
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	14.28
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	9.88
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 9.56

Transition Costs - Additional Information (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Transition Costs [Line Items]
Severance accrual	$ 1,569

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net revenues	$ 233,674	$ 171,721	$ 154,605
Operating income (loss)	(10,164)	(5,177)	18,611
Depreciation and amortization	11,658	9,387	7,339
Capital expenditures	36,622	26,674	9,314
Total assets	460,990	454,472
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	90,040	65,240	78,225
Operating income (loss)	(57,177)	(43,156)	154
Depreciation and amortization	4,325	3,345	3,039
Capital expenditures	26,994	17,860	6,073
Total assets	209,674	242,613
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	143,634	106,481	76,380
Operating income (loss)	47,013	37,979	18,457
Depreciation and amortization	7,333	6,042	4,300
Capital expenditures	9,628	8,814	$ 3,241
Total assets	$ 251,316	$ 211,859

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Business Segment Information - Summary of Operating Segment and Asset Information (Parenthetical) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Purchases of property and equipment under government contracts	$ 11,495
Diagnostics [Member]
Segment Reporting Information [Line Items]
Purchases of property and equipment under government contracts	$ 11,495

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 88,164	$ 51,860
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	76,232	36,897
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	11,003	10,616
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 929	$ 4,347

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
2022	$ 36,721
2023	25,429
2024	16,934
2025	8,667
Total	$ 87,751

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
Estimated penalties to be incurred under minimum purchase commitments	$ 2,209

Commitments and Contingencies - Schedule of Base Salary for Continuing Employment Agreement (Detail) - Employment Agreements [Member] $ in Thousands	Dec. 31, 2021 USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
2022	$ 2,911
2023	821
2024	426
Total	$ 4,158

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	1,295,000	$ 994,000	$ 754,000
Value of the assets associated with the plan	1,763,000	2,565,000
Total obligation under plan	1,763,000	2,565,000
RRSP [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	4,000
Contributed to plan, net of forfeitures	$ 448,000	$ 366,000	$ 184,000